drugset / Trial / NCT03627403
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
Timeline
- Start
- 2019-05-10
- Primary completion
- 2023-08-16
- Completion
- 2025-03-05
Outcome
Outcome not reported
Stopped (Enrollment): “PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |